Harborline: Growth, Working Capital and a Covenant That Steps Down
Harborline Industrial Distribution grew FY2024 revenue 24% to $860 million from $694 million, and EBITDA margin held flat at 11.0%. Operating cash flow fell to negative $29 million from positive $61 million, and capex was $22 million. Days sales outstanding rose from 62 to 78, days inventory outstanding from 71 to 82, and days payable outstanding fell from 45 to 42. Gross margin is 22% and has been stable for three years. Management attributes the build to 'growth and the launch of a national account program,' and one big-box customer now pays on 120-day terms. Net debt is $325 million. The leverage covenant is 3.50x today and steps down to 3.25x at year-end FY2025. FY2025 guidance is 18% revenue growth with 'FCF inflection in the second half.'
1. Decompose the FY2024 working capital change into growth-driven and deterioration-driven components. Which dominates?
Read the worked answer
Setup: revenue per day = 860 / 365 = $2.356M; COGS = 78% x 860 = $670.8M, COGS per day = $1.838M.
Step 1 - total actual build:
| FY2024 | FY2023 | Change | |
|---|---|---|---|
| AR | 78/365 x 860 = 183.8 | 62/365 x 694 = 117.9 | 65.9 |
| Inventory | 82/365 x 670.8 = 150.7 | 71/365 x 541.3 = 105.3 | 45.4 |
| AP | 42/365 x 670.8 = 77.2 | 45/365 x 541.3 = 66.7 | 10.5 |
| Net NWC | 257.3 | 156.5 | 100.8 |
Step 2 - growth component at prior-year day ratios. Incremental revenue $166M; incremental COGS = 166 x 0.78 = $129.5M.
- AR: 62/365 x 166 = 28.2
- Inventory: 71/365 x 129.5 = 25.2
- AP: 45/365 x 129.5 = (16.0)
- Growth-driven = $37.4M
Step 3 - deterioration component. Day-count changes applied at FY2024 volumes:
- AR: 16 days x 2.356 = 37.7
- Inventory: 11 days x 1.838 = 20.2
- AP: 3 days x 1.838 = 5.5
- Deterioration = $63.4M
Check: 37.4 + 63.4 = 100.8. Foots.
Conclusion: 63% of the build is deterioration, not growth. Management's explanation is directionally incomplete. A distributor growing 24% should have consumed roughly $37M of working capital; it consumed $101M. Roughly $63M of that is a change in how the business is being run or in who it is selling to.
2. What does the receivables build imply about revenue quality, and what specific diligence do you request before accepting the 18% growth guide?
Read the worked answer
The 16-day DSO increase is the tell. AR grew far faster than revenue, and management has separately disclosed that a single big-box customer now pays on 120-day terms. That is a terms concession, which is economically a price cut dressed as a payment term - it belongs in your margin analysis, not just your balance sheet.
Diligence requests, in priority order:
- AR aging and the DSO definition. Has management changed how DSO is computed (gross vs net of the allowance, average vs ending balances)? A definitions change can move reported DSO several days with no economic change.
- Is the 120-day program a negotiated term or delinquency? Ask for the customer's payment history pre- and post-program. The distinction changes whether the $37.7M is permanent working capital or a receivable at risk.
- Allowance adequacy. With AR up 56% and one customer now at 120 days, the allowance for credit losses should have moved proportionally. If it did not, FY2024 EBITDA is overstated by the under-provision.
- Revenue recognition timing. Check for bill-and-hold, channel inventory at the big-box customer, and any change in shipping terms (FOB destination vs origin) that shifts revenue earlier without cash.
- Inventory composition. DIO up 11 days alongside a stable 22% gross margin suggests either pre-buying ahead of tariff or cost inflation, or slowing SKUs. Ask for inventory by category and for any last-in-first-out / write-down activity.
- Peer benchmark. If peers are at 55-65 days DSO, 16 extra days is not a growth artifact.
Read on the guide: 18% growth on top of a 30% NWC-to-revenue ratio requires roughly $46M of incremental working capital. If the big-box program is the growth engine, each incremental dollar of that revenue carries a 120-day collection cycle. That is not an FCF inflection story; that is a working capital consumption story with a one-year lag.
3. Test the covenant through FY2025 under your base case and one plausible downside, and say what you would publish.
Read the worked answer
Today: net debt 325 / EBITDA 94.6 = 3.44x against a 3.50x test. Headroom is about $6M of EBITDA, or roughly 6%.
Base case (18% revenue growth, 11.0% margin, NWC held at FY2024's 29.9% of revenue):
- Revenue 860 x 1.18 = 1,014.8; EBITDA = $111.6M
- NWC required = 0.299 x 1,014.8 = $303.4M; increase of $46.1M
- Cash interest ~$20M, cash taxes ~$14M, capex ~$26M
- OCF = 111.6 - 20 - 14 - 46.1 = $31.5M; FCF = $5.5M
- Net debt = 325 - 5.5 = $319.5M; leverage = 2.86x vs the 3.25x step-down. Passes.
Downside (18% revenue growth is delivered, but margin slips to 10.2% and DSO runs 4 days worse):
- EBITDA = $103.5M; NWC to revenue ~30.9% -> $313.6M, increase of $56.3M
- FCF = 103.5 - 20 - 12 - 26 - 56.3 = -$10.8M
- Net debt = $335.8M; leverage = 3.24x - effectively at the 3.25x test.
The covenant floor is $335.8M / 3.25 = $103.3M of EBITDA. The downside case lands on top of it. That means the covenant is not a tail risk; it is a base-case-adjacent risk driven entirely by whether the working capital normalizes.
What to publish: do not carry the 18% guide into your model unadjusted. Assume DSO stabilizes rather than reverts (a 120-day program will not be renegotiated in a growth year), model NWC at 29-30% of revenue, and present the covenant floor in the note. Flag that a 1-day change in DSO is worth about $2.8M of cash at FY2025 volumes, so the difference between a pass and a breach is four days of collections.